Just out todayDigital health tech: Ninety-nine nurses, seventy wearable features, and no control groupDigital health tech: Fifty-six trials, 6,154 patients, and headsets beat the threshold patients would noticeSynthetic biology & cell therapy: Roughly one in four patients on these therapies gets a severe infection

Synthetic biology & cell therapy/Germany, Italy

Twenty-four patients stopped all their immunosuppressants, and stayed off them

A single CD19 CAR-T infusion left 24 patients with refractory autoimmune disease free of all immunosuppressants for 24 weeks.

What the paper found

The CASTLE phase 1/2a basket trial, led from Erlangen with Italian and other European centres, gave 24 patients with treatment-resistant autoimmune disease a single CD19 CAR-T infusion. Primary and secondary endpoints were met: no cytokine release above grade 2, 22 of 24 reaching efficacy endpoints, and all patients drug-free for the full 24 weeks.

Grade 14 reading level7 min read

What happened

The CASTLE trial – CAR-T cells in systemic B cell mediated autoimmune disease – led from Friedrich-Alexander-Universitaet Erlangen-Nuernberg and Universitaetsklinikum Erlangen with the Agostino Gemelli University Polyclinic and further centres, published results in Nature Medicine.

Twenty-four patients with treatment-resistant systemic lupus erythematosus, systemic sclerosis or idiopathic inflammatory myopathies received a single infusion of zorpocabtagene autoleucel, an autologous CD19 CAR-T product.

Primary and secondary endpoints were met. No cytokine release syndrome above grade 2. 22 of 24 patients achieved predefined efficacy endpoints. Every patient remained free of glucocorticoids and all other immunosuppressants for the full 24 weeks.

The test

CAR T cells were engineered to find and destroy cancer cells carrying a specific surface marker. CD19 is the marker on B cells.

In autoimmune disease, B cells produce the autoantibodies and provide the signals that drive inflammation. Conventional treatment suppresses the immune system broadly – steroids, methotrexate, mycophenolate, biologics – which controls disease and brings a lifetime of infection risk and side effects. Deleting the B cells instead is a mechanistically different proposition: reset rather than suppress.

The trial’s structure says a lot about the hypothesis:

– Design: phase 1/2a, two-stage optimal design basket study – Diseases: systemic lupus erythematosus (10), systemic sclerosis (9), idiopathic inflammatory myopathies (5) – Intervention: single infusion, after stopping immunosuppressive treatment and standard lymphodepletion with cyclophosphamide and fludarabine – Primary safety outcome: rate of cytokine release syndrome and immune effector cell-associated neurotoxicity – Secondary efficacy: DORIS remission in lupus; no interstitial lung disease progression in systemic sclerosis; American College of Rheumatology major or moderate response in myopathies, at 24 weeks – Registration: ClinicalTrials.gov NCT06347718; EudraCT 2022-001366-35

The numbers

Outcome Result
Patients enrolled 24 (10 lupus, 9 systemic sclerosis, 5 inflammatory myopathies)
Cytokine release syndrome above grade 2 none
Immune effector cell-associated neurotoxicity none
Patients meeting predefined efficacy endpoints 22 of 24
Lupus reaching DORIS remission 9 of 10
Systemic sclerosis with no disease progression 9 of 9
Myopathies reaching ACR major/moderate response 4 of 5
Free of glucocorticoids and immunosuppressants all patients, entire 24-week period

The result

The drug-free status is the finding that matters most, and it is easy to skim past.

In autoimmune disease, “improved” is a slippery outcome. Patients fluctuate, and most trial participants are improving while still taking background therapy, so attribution is difficult. Here every patient stopped their glucocorticoids and immunosuppressants and stayed off them for 24 weeks – in disease that had already failed conventional treatment. Treatment-resistant lupus does not usually go into drug-free remission on its own.

9 of 9 in systemic sclerosis is the result a rheumatologist will notice. Systemic sclerosis with interstitial lung disease is among the hardest autoimmune conditions to treat and progression is the expectation. No progression in nine patients over 24 weeks is a short observation and a striking one.

The safety result is the trial’s primary endpoint and it passed. No cytokine release syndrome above grade 2, no neurotoxicity. In oncology, severe cytokine release is the complication that makes CAR T an inpatient procedure, and in a non-fatal disease a severe toxicity profile would be disqualifying. Mild toxicity in 24 patients is not a safety guarantee, and it is the right direction.

Now the three limitations that bound all of this.

No control arm. Twenty-four patients, single-arm. The drug-free design mitigates this substantially – spontaneous drug-free remission in refractory disease is implausible – but a basket design with 5 to 10 patients per disease cannot establish efficacy in any one of them.

Lymphodepletion is a confounder, and a potent one. Patients received cyclophosphamide and fludarabine before the infusion. Cyclophosphamide is itself a treatment for lupus, systemic sclerosis and myositis. So a portion of the benefit could come from the chemotherapy rather than the engineered cells, and this trial cannot separate them. That is not a flaw in execution; it is intrinsic to the protocol.

Twenty-four weeks ends before the real question. CD19-directed therapy depletes B cells and B cells come back. Whether disease returns with them – or whether the repopulating immune system is tolerant, which is the hypothesis – is what decides if this is a durable reset. Six months is not long enough to know.

How this compares to what came before

CAR T for autoimmune disease began with case series from this same Erlangen group, which reported drug-free remissions in refractory lupus that attracted enormous attention. CASTLE is the structured trial that follows, which is the right sequence.

Within this batch’s three cell therapy papers:

Study Design Key strength Key weakness
mRNA BCMA CAR T, myasthenia gravis phase 2b randomised double-blind placebo placebo control p = 0.0472 in 26 patients
CASTLE (this paper) phase 1/2a basket, 3 diseases all patients drug-free no control; lymphodepletion confound
Tandem CD19/CD20 CAR T, lymphoma open-label non-randomised 24.3 months median follow-up no control; two changes at once

The myasthenia gravis trial has the stronger design; CASTLE has the stronger raw result. Those two facts are related: the more impressive the uncontrolled numbers, the more a control arm would have been worth.

What the three share is scale – 23 to 26 patients each – and a target: B cells or the plasma cells they become. Three teams on three continents are converging on the same idea, that deleting the antibody-producing compartment can reset autoimmune disease. Separately in this batch, an mRNA approach shows the same targeting can be done without permanent genetic modification, which for lifelong non-fatal disease may matter more than efficacy differences.

What it means

For refractory autoimmune disease, this is the most structured evidence yet that a single CAR T infusion can produce drug-free remission across several conditions.

For trial design, the next step is obvious and difficult: a randomised comparison against lymphodepletion alone would separate the chemotherapy from the cells. It would be hard to justify ethically and it is the experiment the field needs.

For patients, the honest framing is a promising 24-week result in 24 people, with the durability question entirely open.

Business ideas from this paper

Autoimmune-specific CAR T manufacturing. Autoimmune patients are far more numerous than the refractory cancer populations CAR T was built for. Manufacturing designed for volume, cost and outpatient delivery is a different industrial problem from oncology CAR T.

Lymphodepletion-free conditioning. If the chemotherapy is both a confounder and a toxicity source, regimens that prepare patients without cytotoxic agents would improve the therapy and clarify the science.

B cell repopulation monitoring. The question that decides everything is what happens when B cells return. Assays and monitoring services tracking repopulation and autoantibody return would be used in every trial and every treated patient.

Basket trial platforms for mechanism-led therapies. CASTLE’s design – one mechanism, three diseases, disease-specific endpoints – is efficient and statistically delicate. Platforms and statistical expertise for such trials have a growing market.

What could be wrong with it

No control arm: 24 patients across three diseases means 5 to 10 per disease, which cannot establish efficacy in any single condition.

Lymphodepletion with cyclophosphamide and fludarabine is itself an active treatment for all three diseases, and its contribution cannot be separated from the CAR T cells in this design.

Twenty-four weeks of observation ends before B cells repopulate, so durability is unknown and relapse cannot be excluded.

Patients were treatment-resistant and highly selected, so results may not transfer to earlier disease.

No data availability statement was identified in the indexed record.

How sure can you be?

Confident that all 24 patients were off glucocorticoids and immunosuppressants for the full 24 weeks, which is the hardest part of the result to explain away.

Confident in the safety profile at this scale: no cytokine release above grade 2 and no neurotoxicity is a clear, prespecified finding.

Confident that something real happened in refractory disease, because drug-free remission in patients who had failed conventional therapy is not a plausible spontaneous event.

Less confident about how much of the effect belongs to the CAR T cells rather than to lymphodepletion, which this design cannot resolve.

Not confident about durability beyond 24 weeks, nor about efficacy in any individual disease given 5 to 10 patients each.

Our rubric places this in the middle of the range for this batch: peer-reviewed in a leading medical journal, nine institutions across two countries, a prospectively registered trial with prespecified endpoints, no control arm and no public data deposit.

Do this today

When you read a cell therapy result in autoimmune disease, check whether patients stopped their other drugs. That single protocol detail does more interpretive work than the response rate.

Ask what the conditioning regimen was. If it includes cyclophosphamide, part of the answer is already a known treatment for the disease.

If you follow this field, the number to wait for is time to B cell repopulation and what happens after it. Everything else is preamble.

Source: CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial, Nature Medicine, 2026-01-07. DOI 10.1038/s41591-025-04185-6 · doi.org ().

Just Out Tech explains new research in plain language. This article was drafted with AI assistance and checked by a human against the original source.

What to remember
  • CASTLE is a phase 1/2a two-stage optimal design basket study of zorpocabtagene autoleucel, an autologous CD19 CAR-T product, in treatment-resistant systemic lupus erythematosus, systemic sclerosis and idiopathic inflammatory myopathies.
  • Twenty-four patients were enrolled - 10 lupus, 9 systemic sclerosis, 5 inflammatory myopathies - each receiving a single infusion after stopping immunosuppressive treatment and undergoing standard lymphodepletion.
  • No cytokine release syndrome above grade 2 and no immune effector cell-associated neurotoxicity occurred; 22 of 24 patients achieved predefined efficacy endpoints.
  • All patients remained free of glucocorticoids and any other immunosuppressive treatment across the entire 24-week observation period.
Where this really is

Phase 1/2a basket trial with prespecified safety and efficacy endpoints across three diseases; 24 patients, no control arm, 24-week observation.

Questions people ask

What is a basket trial?

One trial that enrols several different diseases sharing a presumed mechanism, treating them with the same therapy and assessing each with its own disease-specific endpoint. It is efficient for a mechanism-led hypothesis - here, that B cells drive all three conditions - and it means no single disease is studied in enough patients to establish efficacy on its own.

Why is the drug-free part so important?

Because in autoimmune disease, improvement while still on immunosuppressants is ambiguous. Every patient here stopped their glucocorticoids and immunosuppressants before the infusion and stayed off them for 24 weeks. Remission without any background therapy in treatment-resistant disease is hard to explain by spontaneous fluctuation.

What is lymphodepletion and why does it complicate interpretation?

Before CAR T cells are infused, patients receive chemotherapy - typically cyclophosphamide and fludarabine - to clear space in the immune system. Cyclophosphamide is itself a powerful immunosuppressant used to treat these very diseases. So part of any benefit could come from the preparation rather than from the CAR T cells, and this trial design cannot separate the two.

Will the disease come back when B cells return?

That is the central unanswered question. B cells repopulate after CD19-directed therapy, and whether the autoimmune disease returns with them, or whether the immune system resets to a tolerant state, determines whether this is a cure or a long remission. Twenty-four weeks is too short to tell.

About the author

Mark Alex

Mark Alex is the founder and Managing Director of Real Biz Digital, a technology company operating out of Nairobi since 2018. He works in agentic AI and the Model Context Protocol, AI governance, enterprise software architecture and cybersecurity. He holds an MSc in Mechatronical Engineering from Obuda University in Budapest and a BSc in IT, Forensic Technology and Cybercrime, from USIU-Africa in Nairobi, and has published IEEE conference research on an AI-powered digital twin for greenhouse systems. He is the author of seven books. Between 2020 and 2024 he mentored more than 200 university students and interns in Nairobi. He writes every Just Out Tech article from the original research paper.